Tevogen Bio Holdings Inc. (NASDAQ:TVGNW – Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,984 shares, a decline of 60.4% from the June 15th total of 5,004 shares. Based on an average daily volume of 154,020 shares, the days-to-cover ratio is currently 0.0 days.
Tevogen Bio Stock Performance
Shares of TVGNW stock opened at $0.05 on Tuesday. The stock’s fifty day moving average price is $0.04 and its 200 day moving average price is $0.04. Tevogen Bio has a 1-year low of $0.03 and a 1-year high of $0.08.
About Tevogen Bio
Tevogen Bio is a clinical-stage biotechnology company focused on developing allogeneic T cell receptor (TCR)-based immunotherapies for the treatment of cancer and infectious diseases. Leveraging a proprietary platform of engineered T cells, the company aims to deliver off-the-shelf cellular products that can recognize and eliminate disease-specific antigens without the need for patient-matched cell manufacturing.
The company’s pipeline encompasses programs targeting chronic viral infections, including hepatitis B virus and SARS-CoV-2, as well as cytomegalovirus, alongside oncology indications such as solid and hematological tumors.
Featured Stories
- Five stocks we like better than Tevogen Bio
- Beyond the Foundry: 5 Infrastructure Stocks Tackling the AI Bottlenecks
- These 3 Stocks Are Beating the Market in 2026 and Just Announced Hefty Dividend Increases
- Baggage Claim: Apollo’s $7.7 Billion Bid to Acquire easyJet
- CEOs Sell Millions Worth of These 3 Big Name Stocks—What It Means for Investors
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.
